MRTX1719
PRMT5 inhibitor preclinical (MTAP-deleted cancers) from fragment-based design + SBDD J. Med. Chem. Mirati Therapeutics
Molecules of the Month - January 2022
Molecules of the Month
- S-217622
- asundexian (BAY2433334)
- compound 1
- GSK3640254
- MIW815 (ADU-S100)
- MRTX1719
- compound 15
- DS-3801b
- LEO 134310
- bradanicline (ATA-101 or TC-5619)